Section 232 Tariffs Get a New Shape: 100% Drug Duties and Reworked Metals Rates

The biggest U.S. trade development of the past week was the Trump administration’s April 2 overhaul of Section 232 tariffs. In one move, the White House paired a new pharmaceutical tariff regime with a restructuring of steel, aluminum, and copper duties, changing both the rate logic and the valuation mechanics that importers need to use starting this week.

Reuters reported that the administration ordered tariffs of up to 100% on certain branded pharmaceutical imports, while also revising metals duties one year after the original “Liberation Day” tariff push. CNBC separately confirmed that patented medications and their active ingredients can face a 100% tariff, with lower rates or exemptions available for companies that negotiate U.S. drug-pricing concessions and commit to domestic manufacturing. USTR framed the broader April 2 action as proof that the administration’s tariff strategy is delivering deficit reduction, reshoring, and new market access.

For importers, the immediate practical issue is that Section 232 is no longer just a simple “50% on metals” story. According to trade compliance guidance from GEODIS, core steel, aluminum, and copper articles listed in Annex I-A remain subject to a 50% tariff on the full customs value of the imported good. But many derivative products in Annex I-B now face a 25% tariff on the full value of the good, rather than a tariff calculated only on the metal content. Some low-metal-content products have been removed from Section 232 coverage altogether, and certain temporary reductions apply through the end of 2027 for eligible steel and aluminum derivatives.

That shift matters because valuation, not just headline rate, drives landed cost. A derivative product that previously required importers to isolate the value of embedded metal may now be taxed on the full entered value. For some products, that simplifies compliance. For others, it raises effective duty exposure even where the nominal rate drops from 50% to 25%. Importers who only look at the new percentage and miss the valuation change are going to misprice entries.

The pharmaceutical side is even more aggressive. Large drugmakers reportedly have 120 days before the full 100% tariff rate applies, while smaller producers have 180 days. Companies that move production to the United States or negotiate pricing arrangements may qualify for lower rates, and some countries with broader trade arrangements appear to have capped or preferential treatment. That means pharmaceutical importers cannot treat this as a uniform blanket tariff. The real exposure depends on product type, sourcing country, deal status, and manufacturing footprint.

The broader signal is political as much as operational. After the Supreme Court struck down the administration’s broader IEEPA tariff program earlier this year, Section 232 has become one of the clearest remaining legal vehicles for sector-specific trade action. April 2 showed that the administration is willing to use it creatively, both to preserve tariff pressure and to recast industrial policy around reshoring, supply-chain security, and domestic production commitments.

For customs teams, the right next move is blunt: recheck classification, origin, and valuation assumptions now. Metals importers should review whether their SKUs fall in Annex I-A, Annex I-B, or Annex II, confirm whether any UK- or U.S.-origin content changes the rate, and revisit broker instructions before entries liquidate under the new rules. Pharmaceutical importers should map exposure by product line and supplier, then model best-case and worst-case outcomes before the grace periods expire.

If you need to quantify the impact, use our landed cost calculator to model stacked duties and fees, then run your SKU through our HTS search tool to confirm the base tariff and product classification. For companies exposed to metals derivatives, this is exactly the kind of week where small classification or valuation mistakes turn into expensive surprises.

The bottom line: April 2 was not just another tariff headline. It was a structural rewrite of how Section 232 now bites, especially for derivative metal products and imported branded drugs. Importers that move fast can still adjust sourcing, pricing, and customs instructions. The ones that wait are going to eat the duty bill.